drugset / Trial / NCT00782626
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Phase 2
Completed
23 enrolled
Dana-Farber Cancer Institute
Novartis · collabThe Pediatric Oncology Experimental Therapeutics Investigators' Consortium · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas. Additionally, the safety of RAD001 will be studied. RAD001 is a drug that may act directly on tumor cells by inhibiting tumor cell growth and proliferation.
Timeline
- Start
- 2009-06
- Primary completion
- 2012-08
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg/m2 | Oral |